Tredje AP fonden Has $3.38 Million Holdings in Zimmer Biomet (ZBH)

Tredje AP fonden lowered its stake in shares of Zimmer Biomet (NYSE:ZBH) by 7.5% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 30,931 shares of the medical equipment provider’s stock after selling 2,500 shares during the period. Tredje AP fonden’s holdings in Zimmer Biomet were worth $3,380,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its position in shares of Zimmer Biomet by 98.8% during the 4th quarter. Wells Fargo & Company MN now owns 2,044,375 shares of the medical equipment provider’s stock worth $246,695,000 after buying an additional 1,016,085 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Zimmer Biomet by 823.1% during the 4th quarter. Two Sigma Advisers LP now owns 739,522 shares of the medical equipment provider’s stock worth $89,238,000 after buying an additional 659,412 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Zimmer Biomet by 14.7% during the 4th quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock worth $576,488,000 after buying an additional 612,044 shares in the last quarter. Longview Partners Guernsey LTD lifted its position in shares of Zimmer Biomet by 6.9% during the 4th quarter. Longview Partners Guernsey LTD now owns 8,027,808 shares of the medical equipment provider’s stock worth $968,716,000 after buying an additional 521,124 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its position in shares of Zimmer Biomet by 56.2% during the 4th quarter. TIAA CREF Investment Management LLC now owns 1,132,003 shares of the medical equipment provider’s stock worth $136,599,000 after buying an additional 407,066 shares in the last quarter. Institutional investors and hedge funds own 86.45% of the company’s stock.

In related news, VP Tony W. Collins sold 1,330 shares of Zimmer Biomet stock in a transaction that occurred on Monday, April 30th. The shares were sold at an average price of $116.73, for a total value of $155,250.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bryan C. Hanson acquired 25,077 shares of Zimmer Biomet stock in a transaction that occurred on Tuesday, February 20th. The stock was acquired at an average price of $119.68 per share, with a total value of $3,001,215.36. The disclosure for this purchase can be found here. 0.71% of the stock is currently owned by insiders.

ZBH has been the topic of several recent analyst reports. Morgan Stanley lifted their target price on shares of Zimmer Biomet from $140.00 to $150.00 in a research report on Monday, January 29th. SunTrust Banks lifted their target price on shares of Zimmer Biomet to $142.00 and gave the stock a “buy” rating in a research report on Monday, January 29th. Needham & Company LLC lifted their target price on shares of Zimmer Biomet from $144.00 to $155.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 30th. Robert W. Baird reissued a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Finally, Stifel Nicolaus raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and lifted their target price for the stock from $120.00 to $168.00 in a research report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Zimmer Biomet currently has an average rating of “Buy” and an average target price of $137.71.

Zimmer Biomet stock opened at $114.50 on Friday. Zimmer Biomet has a 1-year low of $104.28 and a 1-year high of $133.49. The company has a market capitalization of $23.39 billion, a P/E ratio of 14.26, a price-to-earnings-growth ratio of 2.25 and a beta of 1.16. The company has a quick ratio of 1.07, a current ratio of 1.69 and a debt-to-equity ratio of 0.79.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, April 26th. The medical equipment provider reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.89 by $0.02. Zimmer Biomet had a net margin of 21.81% and a return on equity of 14.36%. The business had revenue of $2.02 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same period in the previous year, the business earned $2.13 EPS. Zimmer Biomet’s revenue was up 2.1% compared to the same quarter last year. sell-side analysts forecast that Zimmer Biomet will post 7.67 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 30th. Investors of record on Thursday, March 29th were paid a $0.24 dividend. The ex-dividend date was Wednesday, March 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.84%. Zimmer Biomet’s dividend payout ratio is 11.96%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply